Granstam E, Rosenblad A, Raghib AM, et al. - In patients treated for sight-threatening diabetic macular oedema (DMO) at two Swedish county hospitals, researchers assessed visual acuity (VA) and central retinal thickness (CRT) on optical coherence tomography during a 4-year period, as well as compared health-related quality of life and subjective visual functioning before and after 4 years of treatment. After 4 years of antivascular endothelial growth factor (VEGF) treatment, 48 patients with DMO were assessed. VA, CRT and clinical data have been reviewed retrospectively. Out of 37 of 58 patients, follow-up data were obtained. Regardless of follow-up baseline characteristics were similar. Throughout the study, CRT was reduced. Compared with baseline, SF-36 exhibited no change at 4 years. VFQ-25 showed improvement in near vision activities. In patients with anti-VEGF-treated DMO, significant long-term improvement in visual function was present.